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Fibromyalgia syndrome (FMS) is an incapacitating multifactorial disease 
characterised by widespread pain. Its pathophysiology is still unknown and its diagnosis 
traditionally difficult. New research on possible genetic and epigenetic factors has shed 
light into its possible pathways and better diagnostic methods. The goal of this study is 
to design and implement a diagnostic algorithm for microarray data regarding RNA and 
microRNA expression. To do so, on the one hand, we studied several classification 
methods and tested their adequacy and feasibility given the data and available 
computational power, and on the other hand, we analysed gene expression data in an 
interaction network and microRNA related pathways. The final algorithm used Support 
Vector Machine based Recursive Feature Elimination and holdout cross validation to 
assess the minimum probeset that provided the best accuracy. The results provided a 
set of 56 RNA probes with an accuracy of 95.72% and a set of 20 microRNA probes with 
98.95%. Since it is based on a very limited dataset, the results are not meant to be 
conclusive but to serve as a steppingstone to future studies. The interaction network, as 
well as microRNA analysis provided useful insights into possible FMS-related neural 
system genesis and, specially, inflammatory pathways (through miR-145, miR-150 and 
miR-451 and TNF-α interactions). We advise future work on the subject to finally unveil 
fibromyalgia’s aetiology and provide accurate and useful diagnosis and treatment. 
 
Resumen 
El síndrome de fibromialgia (FMS) es una enfermedad multifactorial incapacitante 
caracterizada por dolor generalizado. Su fisiopatología es aún desconocida y su 
diagnóstico tradicionalmente difícil. Nuevas investigaciones sobre posibles factores 
genéticos y epigenéticos han arrojado luz sobre posibles vías y sobre mejores métodos 
de diagnóstico. El objetivo de este estudio es diseñar e implementar un algoritmo de 
diagnóstico aplicado en datos de microarray de expresión de ARN y microARN. Para 
hacerlo estudiamos varios métodos de clasificación y probamos su adecuación y 
viabilidad dados los datos y la potencia computacional disponible. También analizamos 
los datos de expresión génica en una red de interacción y vías relacionadas con 
microARN. El algoritmo final usó Eliminación Recursiva de Atributos basada en Máquinas 
de Soporte Vectorial y validación cruzada aleatoria para evaluar el mínimo conjunto de 
sondas que proporcionara la mejor precisión. Obtuvimos un conjunto de 56 sondas de 
ARN con una precisión del 95,72% y otro de 20 sondas de microARN con el 98,95%. Dado 
que se basa en un conjunto de datos muy limitado, los resultados no pretenden ser 
concluyentes, sino que sirven como paso para futuros estudios. La red de interacción, 
así como el análisis de microARN proporcionaron información útil sobre posibles vías 
relacionadas con FMS: la génesis del sistema neural y, especialmente, vías inflamatorias 




necesidad de más estudios sobre el tema para finalmente revelar la etiología de la 
fibromialgia y proporcionar un diagnóstico y tratamientos precisos y efectivos. 
2. Integration of academic fields 
The main focus of this project is to analyse genetic and transcriptomic data on 
fibromyalgia syndrome. Hence, this work is mainly framed into the Biochemistry and 
molecular biology field. Moreover, the project also aims to design a classification 
algorithm to apply on such data and hopefully find an objective diagnostic tool for future 
FMS patients. The development of the algorithm implies analysis of machine learning 
methods and statistical tools, subjects from the Mathematics and computer science 
field. Additionally, since the goal of the algorithm implementation is to provide improve 





3. Introduction  
"Having fibromyalgia is like being fifty years older: daily pain, constant effort. 
Everything is twice or three times harder. Thanks to the medication I have some hours 
a day of normal activity, but I can't have a regular job. That was hard to accept. When I 
was 24, I started having pain, but fibromyalgia wasn't known at the time. I began going 
from doctor to doctor; they couldn't find anything specific in all the radiographies and 
analysis. Years later, after the pregnancy, someone recommended I went to an internist 
and he gave the right diagnosis: fibromyalgia. We also went to medical investigation 
centres and to visit specialists in fibromyalgia and rheumatology and we tried to 
participate in studies for new treatments; but the options were few. To better 
understand this illness and to find support, I got myself involved in a fibromyalgia 
patients' association. We also raised awareness of this almost unknown disease. " 
As Mari Carmen Burón, my mother, states, fibromyalgia syndrome (FMS) is an 
incapacitating multifactorial disease. It is characterized by the presence of deep and 
diffuse musculoskeletal pain associated with other subjective manifestations such as 
fatigue, disturbed sleep and variable degrees of anxiety and depression, among others. 
A recent review of the state of the issue (1) reports its prevalence in the general 
population at 2.2 % and that various risk factors have been identified: age, gender, level 
of education and socio-economic status. The main concern about this disorder is that its 
causes have been a mystery. In recent years there has been several hypothesis and 
further breakthroughs about its pathophysiology but there still isn’t consensus on the 
root of the problem.  Neuprez et al. (1) state that, as of 2017, the proposed potential 
mechanisms include genetic predisposition, central amplification, diffuse inhibitory 
control failure, muscle as peripheral nociceptive afferents. Given its characteristics, it is 
not unusual that FMS patients have to suffer from stigma. Some moralizing attitudes, 
disbelief as to the reality of pain, and pain’s invisibility are the main causes of this 
stigmatization of patients (2) and it hinders severely an effective management of the 
disorder.   
The official diagnosis was firstly stablished by the American College of 
Rheumatology in 1990 (3) and it consisted of the presence of widespread pain in 
combination with tenderness at 11 or more of 18 specific tender point sites. However, 
due to its somewhat subjective nature, the diagnosis was rather difficult and usually was 
made by exclusion of other disorders. It was and still is sometimes confused with chronic 
fatigue syndrome, due to a similar symptomatology. There was a revision in 2010-2011 
(4) that included a patient questionnaire in order to better assess the correct diagnosis. 
Later, in 2016, another revision combined physician and questionnaire criteria while 
minimizing misclassification of regional pain disorders and is generally considered an 
improvement over the 1990 criteria (5). 




according to symptoms and other attributes as to better understand it and provide 
better treatment. Docampo and colleagues (6) conducted a cluster analysis of clinical 
data and described three FMS subgroups according to familial and personal 
comorbidities (such as stress disorders, family history of autoimmune disorders, etc.) 
and symptoms and their characteristics (such as muscle weakness, sleep disturbances, 
etc.). Furthermore, for years it has been reported that there exists a familial 
susceptibility of FMS  and Buskila et al. (7) already suggested in 2007 that it may be 
attributable to genetic factors.  
Further investigation into this side of the issue has shed light into the syndrome. 
In 2007 there were reports of evidence that polymorphisms of genes in the 
serotoninergic, catecholaminergic and dopaminergic systems were related to FMS (7). 
In recent years, proteomic analysis has found several possible biomarkers or FMS-
related pathways such as the G-protein coupled estrogen receptor (8), kinins and their 
B1 and B2 receptors in mice (9) and haptoglobin and fibrinogen (10). Clos-Garcia and 
colleagues (11) analysed gut microbiome and metabolome of patients and controls and 
found that the abundance of the Bifidobacterium and Eubacterium genera in patients 
was significantly reduced. They also found there are altered levels of glutamate and 
serine that had correlation to the gut microbiome results, reflecting the effect of the 
microbiome on metabolic activity.  
 Genetic studies have recently vastly improved FMS knowledge. The Al-Ándalus 
project (12) identified associations of the rs841 and rs2097903 SNPs, from the guanosine 
triphosphate cyclohydrolase 1 and catechol‑O‑methyltransferase genes respectively, 
with higher risk of fibromyalgia susceptibility. They also confirmed that the rs1799971 
SNP (opioid receptor μ1 gene) might confer genetic r isk of fibromyalgia.  D’Agnelli and 
colleagues conducted a review on genetic and epigenetic data. They found that beside 
a genetic predisposition, environmental factors also play a fundamental role in the onset 
and development of FMS, through epigenetic modulations. Particularly, FMS patients 
show hypomethylation especially in promoter regions of genes implicated in DNA repair, 
immune system, and membrane transport genes. It is also reported that there are some 
studies that investigated microRNA expression.  
In light of these and several other new findings there has been some development 
of new clinical diagnostic criteria such as the use of using slowly repeated evoked pain 
responses in addition to clinical symptoms to enhance the diagnosis (13). Furthermore, 
there have been new breakthroughs on the use of diagnostic biomarkers such as succinic 
acid, taurine and creatine levels (14) or alpha-enolase, phosphoglycerate-mutase 1 and 
serotransferrin (15). Most of the genetic studies cited above also suggest using the 
found the genetic or transcriptomic differences in diagnosis. 
Even though the studies conducted over the past twenty years have not yet 




important and targeted genetic basis is rather unlikely. Nevertheless, all found genetic 
and transcriptomic modifications related to FMS or to an increased risk of FMS might 
reveal new information and truly prove to be an objective and accurate diagnostic tool.  
4. Objectives  
This study follows two main objectives. Firstly, we aimed to learn to design and 
implement a selective discriminatory algorithm on available microarray data from FMS 
patients. Secondly, we wanted to further assess possible physiopathological causes and 
the use of such data in diagnosis and/or treatment. 
5. Methods 
We conducted a search in several genetic databases (NCBI PubMed, NCBI dbSNP, 
NCBI GEO, OMIM, GWAS Catalog, PheWAS Catalog). Docampo and colleagues (16) 
conducted a genotypic profiling study and found two mutated or modified genes 
associated with FM. However, very few databases provided other useful or relevant data 
for the purpose of this study. The main source of data was the GEO database in which 
we found three relevant studies with available microarray datasets: three studies 
regarding gene expression, gene methylation and microRNA expression in FMS, 
respectively. 
On the one hand,  Ciampi de Andrade and colleagues (17) characterized DNA 
methylome in peripheral blood, using bisulphite converted DNA hybridised to the 
Illumina Infinium 450k Human Methylation Beads. They found changes in genes 
implicated in immune system and showed relation to a dysfunctional connectivity in 
pain network. On the other hand, Jones et al. (18) analysed gene expression in whole 
blood samples of FMS patients and healthy matched controls. The RNA was isolated 
using the PAXgene RNA isolation kit and total RNA was quantified afterwards on a 
Nanodrop spectrophotometer and only samples with good quality RNA (RNA integrity 
number > 8) were processed to be hybridized to Affymetrix® Human Gene 1.1 ST Peg 
arrays. They found that genes related to inflammatory pathways were hyper-expressed 
while specific pathways related to hypersensitivity and allergy were hypo-expressed, as 
well as known pathways for pain processing and axonal development were differently 
expressed. They used a Support Vector Machines-based algorithm to classify samples 
into either patient or control classes and tested their results with corrections for 
optimism based on the bootstrapping method, applied to the model generated using a 
Logistic Regression algorithm. 
Apart from methylation and RNA expression data, another microarray dataset was 
obtained regarding microRNA expression in FMS patients and matched controls.  




several protein-coding genes (19). miRNA attaches to the target mRNA by base-pairing 
to downregulate its expression and, as so, negatively regulate protein synthesis. miRNA 
profiles (miRnome) have been analysed in several diseases to find out whether it plays 
an important role in their aetiology or physiopathology. miRNome profiles are actually 
altered in specific tumours, indicating that miRNA might be implicated in the 
development of cancer and other diseases (19). The importance of miRNA-mediated 
gene regulation indicates that the study of miRNome in FMS might unveil new 
information. Cerdá-Olmedo et al. (20) conducted a study to identify changes in 
miRNome of FMS patients to, firstly, develop a quantitative diagnostic method and, 
secondly, provide a deeper understanding of FM. miRNA samples were extracted from 
peripheral blood mononuclear cells of FMS patients and population-age-matched 
controls using human v16-miRbase 3D-Gene microarrays (Toray Industries, Japan). 
Selected miRNAs were further validated by RT-qPCR. They found a marked 
downregulation of 4-fold or more of hsamiR223-3p, miR451a, miR338-3p, miR143-3p, 
miR145-5p and miR- 21-5p. About 20% of the miRNA were hypo-expressed (2-fold or 
more). They concluded that this might implicate a general de-regulation of the miRNA 
synthetic pathway in FM. Nonetheless, they found no significant correlations between 
miRNA inhibition and FMS fundamental symptoms. 
Onwards, these three datasets will be referred to as DM (DNA Methylation), GE 
(Gene Expression) and ME (miRNA Expression), respectively. 
5.1. Algorithm design 
The diagnosis of a patient can be modelled through a classification problem, such 
that, given a series of values belonging to some features, we can decide if they 
correspond to either a (+) or a (-) class, patient or healthy control, respectively. These 
features could be glycohemoglobin blood levels in diabetes diagnosis or blood pressure 
in arterial hypertension. The development of genetic techniques provides substantial 
opportunities in classification through genetic data (21). In these cases, the input data 
is a vector consisting of N features: gene expression or methylation coefficients for N 
genes, among others.  
In order to develop such a classification model, we need a training set of vectors X 
(corresponding to patients and controls) with known class labels Y. For example, X 
correspond to the probe expression coefficients for all patients and controls and Y, to 
either +1 or -1 if the given sample is from the patient or control classes, respectively. 
  .  
   
These training vectors are used to generate a decision function . Once built, it 
can be used to classify new patterns: 





The decision function can be a simple weighted sum of the training vector plus a 
bias, a linear discriminant function: 
 
where  is the weight vector and  is a bias value. 
In the case of using genetic data in a classification problem, usually the number of 
features is very high (thousands of genes) and the number of training patterns is smaller 
in comparison (the number of patients and controls). In such cases the problem of data 
overfitting can arise; it is easy to find a  that separates the training but will classify 
poorly test data. To avoid the issue, it’s not unusual to perform algorithms that reduce 
the dimensionality of the vector space. 
One such method is projecting on the first few principal directions of the data, 
obtaining new features that are linear combinations of the original features (22). 
However, this implies that one cannot discard any of the original features, even though 
some might be irrelevant to the classification.  Given that the objective is to build 
diagnostic tests, we need to select a small subset of genes due cost effectiveness and 
ease of verification of the results. 
The simplest way to find such subset would be to exhaustively train the decision 
function to all subsets of features and selecting the one with highest discriminatory 
power with test data. However, it is obvious that exhaustive enumeration on large 
numbers of features is highly impractical.  
Feature selection in such cases can be achieved through various methods; feature-
ranking being especially useful (21). If all features are ranked according to a ranking 
function, we can select a fixed number of the top features or establish a threshold on 
the ranking criterion. Furthermore, it is possible to use the ranking to defined nested 
subsets of the feature space leaving out successively the lowest ranked feature. In doing 
so, we can find an optimum subset of features modifying only one variable: the number 
of features.  
In order to apply feature selection to the available data, we firstly proposed using 
correlation classifiers as Lukkahatai et al. performed in 2018 (23). They attempted to 
apply a predictive algorithm to identify a group of genes whose differential expression 
discriminated individuals with FMS diagnosis from healthy controls.  
They followed the predictive algorithm using filter methods and recursive feature 
elimination established by Saligan and colleagues (24). These researchers studied the 
difference between nonmetastatic patients that developed fatigue and those that did 
not during radiation therapy, and through raw microarray transcripts from whole-blood 
RNA, they identified genes that discriminated from both classes. Lukkahatai et al. (25), 
similarly, applied raw microarray gene expression data from peripheral blood 
mononuclear cell RNAs of FMS subjects and age- and gender-matched healthy controls 




(FR) as feature ranking criterion. The discriminatory accuracy of the gene subset was 
established via leave-one-outcross-validation (LOOCV) iterating over all the samples. 
The decision function in the subset was based on a nearest-neighbour classifier (k-NN).  
However, as Guyon et al. state, correlation classification methods select the genes 
that individually classify best the training data (21). The feature elimination procedure 
usually does not yield compact subsets because gene data is redundant and also it 
eliminates genes that individually do not separate the data but do when considered 
together. A good feature ranking criterion is not necessarily a good feature subset 
ranking criterion.  
Taking this information into consideration, we decided to use, as the original study 
our GE data is from, Support Vector Machines (SVMs). 
5.1.1. SVM 
SVMs are machine learning models with associated learning algorithms that map 
the data examples of separate categories (in this case a binary separation between 
patients and healthy controls) so that they are divided by a clear margin that is as wide 
as possible. More formally, a SVM builds a hyperplane or set of hyperplanes in a high-
dimensional space (22), as seen in figures Figure 1 and Figure 2. 
Guyon et al. demonstrated that SVMs are very effective for discovering informative 
features and that they have quantitative advantages over other gene selection models. 
If the training dataset, X, is linearly separable, a linear SVM is a maximum margin 
classifier (26). The decision boundary (the hyperplane that separates data points from 
each class) is located to leave the largest possible margin on either side, so that the 
classification can be as robust as possible. In SVMs, the weights  of the decision 
function  depend only on a small subset of the training points. Those are the 
examples that are closest to the decision boundary and lie on the margin and they are 







Figure 1: example of a 2D SVM classification where 
the central line represents the decision function and 
the dotted lines, the margin limits designated by the 
support vectors (data points on the lines) 
Figure 2 :example of a 3D SVM classification in which 
the dotted plain represents the decision function 
 
The decision boundary is defined by the weight vector , which is perpendicular to 
the hyperplane. Given a new data point, noted by vector , the decision function will 
indicate if it falls on either side of the decision boundary, mathematically either: 
 
 
The constraint of finding the hyperplane with the largest margin is crucial in the 
optimization of  and . In order to do so, we define the two hyperplanes that define 
the margin, given by the support vectors (as seen in Figure 1 as a 2D example). These 
are defined as  
 
 
for all (+)-class and (-)-class support vectors. Taking into consideration the class 
labels, : 
 
This equation is the formal constraint for support vectors that allows us to calculate 
the optimal weight vector and bias. The constraint function for every featureset is, 
simply, that the above result has to be greater than or equal to 0, since we want that 
the training data do not fall within the decision margin even though unknown data might 
do so.  
Therefore, our goal is to maximize the width between separating hyperplanes: 
minimizing the magnitude of the weight vector, , and maximizing , with the 




This problem is quadratic with linear inequality constraints, so in order to solve it 
we can use Lagrange multipliers: 
 
Then we substitute into the Lagrange primal function the corresponding derivatives. 
Finally, the training of the SVM given a training dataset X and Y consists of minimizing 
the following equation over : 
 
 
Subject to  
 
The result is the list of parameters  which is used to calculate both  and , most 
 being equal to 0. C is a positive soft margin parameter that ensures convergence even 
when the problem is non-linearly separable. As stated by Guyon et al. in the case of 





As we stated before, in cases where the dimensionality of the feature space is very high, 
it is useful to perform feature elimination. We can, therefore use the SVM to assess the 
importance of each feature for the classification of the data and successively eliminate 
the least important features; such a procedure is SVM-based recursive feature 
elimination (SVM-RFE) (27).  It is a specific application of recursive feature elimination 
that uses the weight magnitude as ranking criterion of the features. An outline of the 
algorithm is as follows: 
• Given training datasets X,Y, initialize the subset of surviving features s and 
the ranked feature list r: 
 
 
• Train the classifier  
• Compute the weight vector of dimension length |s| 
 
• Compute the ranking criteria for all i 
 





• Update r by adding f 
• Eliminate f from s 
• Repeat until   
5.1.2. Internal Validation 
The resulting SMV model, after applying RFE to a certain number of features, 
should, therefore, classify new datasets into either class and, as such, act as a diagnostic 
criterion. However, it is essential that its performance is tested and validated. Given the 
limited amount of data available and that repeating the sample collection and 
processing is highly impractical, we resort to internal validation methods (28). In general, 
they split the available data into two subsets, one to train the model and the other to 
test it. 
Jones et al. used a bootsrapping-based method to assess the discrimination of the 
optimal and minimal probeset. According to Efron and colleagues (29), the most efficient 
validation is achieved by computer-intensive resampling techniques such as the 
bootstrap.  Bootstrapping imitates the process of sampling from an underlying 
population by generating samples with replacement from the original data set (28).  
However, due to computational constraints, we decided to apply classical cross-
validation methods following a similar procedure to Saligan et al. 
5.1.3. Final Algorithm 
In summary, after assessing several algorithms and methods and the feasibility 
with our available assets, we designed the final algorithm to be applied to both the GE 
and ME datasets. The first dataset, since Jones et al. already applied a more powerful 
SVM-based algorithm on it, will serve as a reference to assess the external validity of the 
results. All procedures were implemented in Python 3.7.6 using the numpy, pandas and 
scikit-learn libraries. 
Firstly, data from all features was normalized according to the  samples and then 
defined into X,Y sets, X containing all  vectors with the expression profile and Y, all   
class labels for each sample  . These sets were then divided into random paired training-
testing subsets such that the testing subset contained  elements. Both cohorts had 
equal representation of FMS. 
Next, SVM-RFE was performed through training the SVM-classifier with the 
training dataset, calculating the weight and ranking of each feature and recursively 
eliminating the lowest ranking one until a variable number of features was achieved. 
The accuracy of the reduced featureset was tested through 2000 iterations of k cross-
validation, all accuracy values were stored in a data matrix. 
The whole process was repeated 10 times for each number of features, k. The 










They were selected by successive addition of powers of 2 so as to cover a greater range 
of k without computing all natural numbers in-between.  
 The X,Y sets that were used in the algorithm were subsets and did not contain all 
features from the microarray datasets. Since GE dataset contains 33297 probes 
(features) and ME only 1213, the former was used to assess the computational 
capabilities and the limits on the algorithm. The algorithm was tested by including 
increasing number of features into the X,Y sets. Including more than 8000 features 
exceeded the available computational power.  
Therefore, less than 8000 could be included from the GE and ME datasets. In order 
to select the features to be included we performed a correlation ranking as proposed at 
the beginning of the algorithm design. All features were ranked according to their 
Fischer’s Ratio (FR) and the top 8000 features were selected to perform the algorithm. 
5.2. Microarray data general analysis 
Apart from performing the classification algorithm on GE and ME data, and taking 
into consideration that the results discussed in section 6.1 did not provide truly useful 
insights into the role of epigenetic data in FMS, we decided to analyse the three datasets 
in parallel to the algorithm by selecting the 250 top differentiated probes for all datasets 
(by ranking through |FC|). 
The data obtained for DM and ME can be observed in Table 1 and Table 2. It is 
important to note that the fold change is calculated by 
 
Where  and  are the mean coefficients for patient and control classes 
for probe i. The fold change values represent different magnitudes in each dataset: in 
DM they represent methylation levels and in GE, RNA levels. Even though a gene with 
high methylation is usually underexpressed and, as such, these magnitudes affect in 
opposite directions, the changes in both parameters are indicative of gene expression 
changes.  
We firstly selected 80 of the most differently expressed genes for each subset to be 
input in the STRING database so as to create a protein interaction network. However, 
no satisfactory networks  were obtained. Therefore, we input all 250 genes from each 











Relation to UCSC 
CpG Island 
cg26044428 4.75e-07 0.415 1.333  ANGEL1 Island 
cg10140678 2.67e-10 -4.013 0.062   N_Shore 
cg03517506 4.76e-08 0.537 1.451  ANKRD36 N_Shore 
cg09413645 4.71e-07 -3.039 0.122    
cg02458875 2.96e-09 -2.402 0.189 rs72843885  N_Shore 
cg12817782 5.17e-08 0.666 1.587  ANO1 Island 
cg11094953 5.41e-07 0.311 1.241  ARCN1 N_Shore 
cg14930904 1.25e-07 0.475 1.390  ARHGAP12 N_Shore 
cg01019484 1.77e-07 -1.659 0.317    
cg03794530 9.03e-08 -1.654 0.315   N_Shore 
Table 1: first 10 items from DM data with calculated FC (in alphabetical order of Gene Symbol)  




8128795 1.24e-03 0.178 0.884 AK9 adenylate kinase 9 
7892779 2.67e-04 0.56 0.678   
7893526 2.67e-04 0.56 0.678   
8122807 3.32e-05 0.200 0.871 AKAP12 A-kinase anchoring protein 12 
8150439 3.21e-03 -0.294 1.226 ANK1 ankyrin 1 
7895647 7.71e-04 0.506 0.704   
8069511 2.76e-03 0.249 0.842 ANKRD20A11P ankyrin repeat domain 20 family member A11 
8069508 3.44e-04 0.479 0.718   
7919139 1.12e-03 0.179 0.883 ANKRD20A12P ankyrin repeat domain 20 family member A12 
7919146 1.71e-03 0.181 0.882 ANKRD20A8P ankyrin repeat domain 20 family member A8 
Table 2: first 10 items from GE data with calculated FC (in alphabetical order of Gene Symbol) 
 
 
Figure 3: protein interaction network from GE data in 
STRING database (high confidence) 
Figure 4: protein interaction network from DM data 





Nonetheless, as we could only find one gene that appeared in both subsets, the 
comparison of both networks would probably be unfruitful, thus, we combined all genes 
and (their respective FC values) in a single dataset to be input in the STRING database. 
Some formatting work was needed to achieve better results (namely, eliminating 
duplicates, commas and other punctuation symbols, etc.). The network we obtained 
(Figure 5) was difficult to analyse due to the high number of nodes and edges and due 
to the lack of the expression data. We did have a succesful protein interaction network, 
but no readily available information about the difference in expression in FMS.   
 
 
Figure 5: protein interaction network from GE and DM conjoined data in STRING database (medium confidence)  
In order to create a network which included the expression data, we downloaded 
the graph information from the STRING database. We obtained an incidence list with 
scores for each edge (weight) and additional information on each node. The edge scores 
were calculated by STRING according to the confidence of the given interaction. We put 
together the incidence list and weight with the FC for each node and the dataset node 
1 was part of (to facilitate further identification). Table 3: random 10 item incidence list from 
conjoined STRING and expression data represents a random 10-row sample from the conjoined 








Node 1 Node 2 Score FC node 1 FC node 2 Dataset 
TERF2IP HIST2H2BE 0.900 1.515 1.303 DM 
TFAP2B YEATS4 0.964 1.724 2.241 DM 
TFB1M HCFC1 0.902 1.285 0.531 DM 
TFB1M NOP9 0.575 1.285 1.477 DM 
TFB1M PPP5C 0.436 1.285 1.313 DM 
TFB1M RPL10 0.405 1.285 1.213 DM 
TIMM10 ATP5B 0.902 1.274 1.227 DM 
TIMM10 IMMT 0.558 1.274 1.453 DM 
TNS1 SLC4A1 0.708 1.210 1.229 GE 
TNS1 BCL2L1 0.498 1.210 1.144 GE 
Table 3: random 10 item incidence list from conjoined STRING and expression data 
The incidence list was converted into an adjacency matrix which included the 











































AKD1 0 0 0 0 0 0.645 0.445 
ANK1 0 0 0 0.901 0 0 0 
ANKRD36 0 0 0 0 0 0 0 
ARCN1 0 0.901 0 0 0 0 0 
ASB7 0 0 0 0 0 0 0 
ATP5B 0.645 0 0 0 0 0 0.928 
ATP6V1A 0.445 0 0 0 0 0.928 0 
Table 4: 7x7 extract from adjacency matrix of table 5 data 
The adjacency matrix along with node attribute list (the FC value of each node) 
was then processed in the Gephi network analysis software. It resulted in a graph (Figure 
6) in which proteins and their interactions as well as their expression value (indistinctly 
as methylation and RNA expression FC) are represented. The thickness of the edges 
indicates the confidence according to the STRING database and the colour of the nodes 
indicate the FC in the following scale: red for hypo-differentiated genes (FC<0), green 
for non-differentiated genes (FC=0) and blue for hyper-differentiated genes (FC>0). The 







Figure 6: protein interaction network from DM, GE and STRING data. The thickness of the edges indicates the 
confidence according to the STRING database and the colour of the nodes indicate the FC (red for FC<0, green for 
FC=0, and blue for FC>0). Dotted lines represent clusters, defined imprecisely, of highly differentiated gene. 
 
6. Discussion 
6.1. Algorithm results 
After computing the algorithm on any set of data, the results consist of the set of 
selected probes for each of the 10 iterations of the SVM-RFE, each containing k probes 
for all k in the corresponding array (27 and 34 different values of k for the GE and ME 




2000 iterations on the 5-fold cross-validation, such that for any k we obtained 20.000 
values of accuracy in percentage. The algorithm, although yielding good accuracy 
results, shown and discussed in subsequent sections, is deemed in need of 
improvement.  
 
Figure 7: histogram of FR in GE dataset, the dotted line represents the 8000th FR value, data points below this are 
not included on the algorithm 
We included only data from the 8000 top differentiated features through FR 
ranking, forcibly leaving out 76% of the available features in the GE dataset (Figure 7). 
Even though it might be logical that the mostly differentiated features between FMS 
patients and controls provide the better discriminatory power, genes, as stated, are 
redundant and this initial feature selection might leave important features out of the 
algorithm. In consequence and to fully analyse the data, the algorithm needs better 
implementation and optimization tools and higher computational power.   
6.1.1. GE dataset  
From the original 33297 features, the data input to the algorithm consisted of 
8000 features with 141 samples (67 FMS and 75 healthy controls). The mean accuracy 
obtained in this dataset was 85.63% (CI 81.72- 89.54 %). However, the relationship 
between accuracy and the number of selected features is clear in Figure 8. The data 
points show a good linear correlation (p<0,05) from 64 to 256 features, reaching 
accuracy values between 92 and 96% (Figure 9). The actual highest accuracy, however, 
corresponds to the probesets with 56 features: 95.72% (CI 95.55-95.90%). Even though 
the regression yields better accuracy at longer probesets, we decided to further analyse 









Figure 8: mean accuracy versus number of features achieved in 
SVM-RFE for the GE data 
Figure 9: linear regression of mean accuracy versus k and CI 
region (dotted lines) for k≥64 
The specific accuracy results on the 10 iterations of the 56 features-probeset are 
shown in Figure 10. These sets did not fully coincide, they all included some features but 
most of them were not shared between all 10 sets. As a consequence, we decided to list 
all appearing features and rank them according to their frequency between all 
probesets, such that probes that were included in all 10 sets were ranked first. We then 
selected the top 56 features to create a new probeset (TOP) that might, as a hypothesis, 
have better accuracy. Its results are also shown in Figure 10. 
 
Figure 10: accuracy boxplots for all 10 iterations of SVM-RFE at k=56 and TOP probeset (56 most frequent probes in 
the previous sets); the dotted lines are the mean accuracy and CI for all k 
The difference in accuracy was tested through a one-way analysis of variance with 
post-hoc Dunnett’s test comparing each probeset to the TOP set. Figure 11 shows that 
the new set yields better results than most of the previous sets except for probeset 1. 
When contrasting them, turns out that 38 out of the 56 features in both sets are shared 






















This might provide an explanation to 1 and TOP not being statistically different in 
accuracy. 
 
Figure 11: Dunnett's test results, if an interval does not contain zero, the mean accuracy is significantly different to 
the TOP probeset 
Finally, we input all probe IDs from the TOP probeset into DAVID database so as 
to get the gene the probe corresponds to (Table 5). 
Probe ID Gene Name Gene Symbol FC LogFC FR 
8083260 carboxypeptidase A3 CPA3 0.008 1.006 0.029 
7927548 translocase of inner mitochondrial membrane 23 TIMM23 0.005 1.004 0.030 
8179559 prefoldin subunit 6 PFDN6 0.016 1.011 0.030 
7895158   0.021 1.015 0.030 
8098342 Sin3A associated protein 30 SAP30 0.011 1.007 0.030 
7990815 suppressor of tumorigenicity 20 ST20 0.027 1.019 0.030 
8073842 tetratricopeptide repeat domain 38 TTC38 0.008 1.006 0.030 
8046527 homeobox D12 HOXD12 -0.007 0.995 0.030 
8048114   -0.016 0.989 0.031 
8015349 keratin 19 KRT19 -0.012 0.991 0.031 
8037315 pleckstrin homology like domain family B member 3 PHLDB3 0.007 1.005 0.031 
8149289 SRY-box 7 SOX7 0.015 1.011 0.031 
8008868   0.014 1.010 0.031 
8139031   0.013 1.009 0.031 
8171026 H2A histone family member B2 H2AFB2 -0.022 0.985 0.031 
8058591 acyl-CoA dehydrogenase, long chain ACADL -0.012 0.992 0.031 
7894806   0.015 1.010 0.031 
8032804 SH3 domain containing GRB2 like 1, endophilin A2 SH3GL1 0.006 1.004 0.031 
8169598 zinc finger CCHC-type containing 12 ZCCHC12 0.019 1.014 0.031 
7895793   0.030 1.021 0.031 




8109350 solute carrier family 36 member 1 SLC36A1 -0.011 0.993 0.031 
7994541 linker for activation of T-cells LAT -0.008 0.994 0.031 
7893149   0.009 1.007 0.031 
7986755 MAGE family member L2 MAGEL2 0.009 1.006 0.031 
7913705 cannabinoid receptor 2 CNR2 -0.012 0.992 0.031 
7894857   -0.024 0.984 0.031 
8000676 nuclear pore complex interacting protein family member B5 NPIPB5 0.019 1.013 0.032 
7909441 G0/G1 switch 2 G0S2 0.014 1.010 0.032 
8120194 transcription factor AP-2 beta TFAP2B -0.010 0.993 0.032 
8122705 protein-L-isoaspartate , D-aspartate O-methyltransferase PCMT1 0.012 1.009 0.033 
7965627 leukotriene A4 hydrolase LTA4H 0.014 1.010 0.033 
7971134 proline and serine rich 1 PROSER1 0.013 1.009 0.033 
8124394 histone cluster 1 H2B family member b HIST1H2BB -0.008 0.994 0.033 
7994308 KIAA0556 KIAA0556 -0.015 0.990 0.037 
7970388 ankyrin repeat domain 20 family member A9, pseudogene ANKRD20A9P -0.066 0.955 0.037 
7894365   0.018 1.013 0.039 
7892545   0.017 1.012 0.041 
7896535   0.017 1.012 0.044 
8083463 chromosome 3 open reading frame 79 C3orf79 0.016 1.011 0.045 
8149629 GDNF family receptor alpha 2 GFRA2 0.017 1.012 0.047 
8158059 syntaxin binding protein 1 STXBP1 -0.021 0.986 0.050 
8125447 major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 -0.033 0.977 0.051 
8069517 ankyrin repeat domain 20 family member A9, pseudogene ANKRD20A9P 0.018 1.013 0.054 
7895033   0.013 1.009 0.057 
8090469 GATA binding protein 2 GATA2 0.017 1.012 0.058 
8113664   0.020 1.014 0.059 
8165752 interleukin 3 receptor subunit alpha IL3RA 0.029 1.021 0.065 
7925448   0.009 1.007 0.076 
8044124 G protein-coupled receptor 45 GPR45 0.024 1.017 0.079 
7972936 transmembrane protein 255B TMEM255B -0.024 0.983 0.082 
7896649   0.021 1.014 0.099 
7893252   -0.017 0.988 0.103 
7949971 carnitine palmitoyltransferase 1A CPT1A -0.023 0.984 0.107 
7894782   -0.030 0.979 0.109 
8155248   0.038 1.027 0.139 
Table 5:  set of 56 gene expression probes that yields best accuracy results 
A characteristic to note from these probes is that they do not correspond to the 
most differentiated probes in the whole GE dataset. They actually mostly fall on the low 
end of the FR distribution as seen in Figure 12. This result further confirms Guyon and 







Figure 12: histogram of FR with superposed FR boxplot for the 56 probes included in the selected set 
On the one hand, from the most selected features, only CPA3 corresponds to one 
of the most discriminatory genes according to Jones et al. They found that the most 
accurate probesets included only 10 features in contrast to the 56 we found.  However, 
their 10-long probeset yielded an accuracy of about 95%, while our 56-long probeset 
yielded 95,72%. On the other hand, Lukkahatai and colleagues (23) found a 57 features-
long set to be more accurate but none of their selected features matched our set. These 
results confirmed our initial suspicions that, given the stochastic nature of the algorithm 
(due to the 5-fold data split for validation and training and leaving 76% of probes out), 
the algorithm wouldn’t yield the same probeset.  
6.1.2. ME dataset 
The original dataset consisted of 1212 features with expression coefficients for 21 
samples (from 11 FMS patients and from 10 and healthy controls). Several values were 
registered in the GEO database as NULL. Even though the algorithm can compute all 
features (less than 8000), we decided to drop any feature with less than 10 samples or 
less than or equal to 5 or 6 in the control and the FMS classes, respectively. The reason 
is to only use the features whose data we deemed trustworthy as having less than 10 
sample could prove statistically deficient. Those features were eliminated, and the 
resulting dataset was updated by substituting all remaining NULL values with -9999 such 
that the algorithm recognised them as outliers. In doing so, we did not get many data 
points, since only 259 features did not have missing attributes. The final dataset 
contained 454 features. 
The mean accuracy obtained through all probesets was 98.25% (CI 97.96- 98.54 %) 
and there seemed to be no readily identifiable correlation between accuracy and the 
number of selected features (Figure 13). This, as well as the mean accuracy, is clearly 
different from the previous results as seen in Figure 14. The microRNA dataset used 




controls than the RNA expression dataset. The highest accuracy corresponds to the 
probesets with 20 features: 98.95% (CI 98.88-99.01%).  
 
  
Figure 13: mean accuracy versus number of features achieved in 
SVM-RFE for the ME data 
Figure 14: mean accuracy versus number of features achieved in 
SVM-RFE for ME (red) and GE (blue) datasets 
Following the previous procedure, Figure 15 shows the specific accuracy results on 
the 10 iterations of the 20 features-probeset as well as the new TOP probeset 
(constructed with the most frequent probes). The results of the comparison between 
each iteration and the TOP set are also shown in Figure 16.  
 
Figure 15: accuracy boxplots for all 10 iterations of SVM-RFE at k=20 and TOP 
probeset (56 most frequent probes in the previous sets); the dotted lines are the 
























Figure 16: Dunnett's test results, if an interval does not contain zero, the 
mean accuracy is significantly different to the TOP probeset 
The results state that the new probeset was not more accurate than most of the 
previous sets. However, since it is composed by the most appearing features in the other 
sets, we show its elements in Table  6, as well as the microRNA descriptor, FC. 
Probe ID microRNA FC 2FC 
MIMAT0001631 hsa-miR-451 -3,679 0,078 
MIMAT0000280 hsa-miR-223 -2,735 0,150 
MIMAT0000078 hsa-miR-23a -2,235 0,212 
MIMAT0000433 hsa-miR-142-5p -2,080 0,237 
MIMAT0000067 hsa-let-7f -1,999 0,250 
MIMAT0000076 hsa-miR-21 -1,994 0,251 
MIMAT0000101 hsa-miR-103 -1,989 0,252 
MIMAT0000074 hsa-miR-19b -1,985 0,253 
MIMAT0000065 hsa-let-7d -1,941 0,260 
MIMAT0000418 hsa-miR-23b -1,920 0,264 
MIMAT0000062 hsa-let-7a -1,905 0,267 
MIMAT0000417 hsa-miR-15b -1,883 0,271 
MIMAT0000069 hsa-miR-16 -1,877 0,272 
MIMAT0000100 hsa-miR-29b -1,756 0,296 
MIMAT0000082 hsa-miR-26a -1,569 0,337 
MIMAT0000086 hsa-miR-29a -1,306 0,404 
MIMAT0000414 hsa-let-7g -1,057 0,481 
MIMAT0016916 hsa-miR-4286 -0,991 0,503 
MIMAT0000451 hsa-miR-150 -0,609 0,656 
MIMAT0015041 hsa-miR-1260b -0,369 0,774 
Table  6: set of 20 miRNA expression probes that yields best accuracy results 
From this set of miRNA probes we can see all features present down-regulation 





6.2. General analysis 
DNA methylation is a quite relevant method of gene expression regulation, 
therefore, important in embryogenesis, genetic imprinting, and X chromosome 
inactivation. Methylation profiles change across the genome due to epigenetic factors 
and the aging process (30). DNA methylome analysis as a mean to better understand 
causes and/or possible treatments for FMS is, therefore, a good course of action. Gene 
expression changes might be determinant to some symptoms or, maybe, acquired 
epigenetic changes are the underlying cause for the onset of this disorder.  
According to Menzies et al. (31) significant differences in DNA methylation 
patterns were found between healthy controls and FMS patients. Mostly, those changes 
were due to an increased methylation in women with FMS, located in relevant biological 
clusters involved in chromatin compaction, nervous system development and 
skeletal/organ system development. They also compared the frequency of 
spontaneously occurring micronuclei, which are small nuclei that occur when a 
chromosome or a fragment is not integrated in one of the daughter nuclei during 
mitosis. They usually indicate genotoxic episodes and chromosomal instability, 
commonly seen in cancerous cells (32). They may also increase the risk of developmental 
or degenerative diseases. The mean micronuclei incidence of women with FMS was 
significantly higher than that of healthy controls. 
The DM data (Table 1) includes the column "Relation to UCSC CpG Island" which 
indicates the position of the differently methylated nucleotide with respect to a CpG 
island (included in the USCS Genome Browser database). One of the basis of DNA 
methylation is the transfer of a methyl group from S-adenosyl-L-methionine to the 
cytosine of a CpG dinucleotide (cytosine and guanine nucleotides adjacent in the same 
strand) (33). This methylation in cytosine mostly occurs when being adjacent and five 
prime to guanine (hence, the nomenclature of CpG). DNA methylation is a major 
mechanism to modulate chromatin access of transcription factors and the basal 
transcriptional machinery. About 15% of the CpG sites are inside CpG islands in the 
promoters of some 70% of protein-coding genes (33). CpG islands are generally between 
300 and 3000 bp long and with a GC content of greater than 50%. It is clear that CpG site 
methylation plays a major role in gene expression modulation (33). Furthermore, CpG 
islands that previously seemed to not be associated with any known genes, have been 
associated with long non-coding RNA (lncRNA), miRNAs and other non-coding genes, 
and these orphan CpG islands may be important in the control of non-coding RNA 
expression (34). In DM, the great majority of most differently methylated sites were in 
N-shores in relation to a CpG island, giving rise to the idea that FMS might be significantly 
related to gene dysregulations. 
In order to further analyse the interaction network, we obtained in section 5.2, it 
would be best to have the mean values of either methylation or RNA expression for each 




so as to try to unfoundedly convert gene methylation into RNA expression values. 
Hence, FC values are taken into consideration as a general gene dysregulation. We 
located nodes that had either red or blue colour and preferably high degrees and heavy 
edges (indicated with arrows in Figure 6). Data from the GeneCards database provided 
information on the function and/or properties of every relevant node (Table 7).  
 
CDC34 
Ubiquitin-conjugating enzyme; catalyzes the covalent attachment of ubiquitin to 
other proteins. This protein is a part of a large multiprotein complex required for 
ubiquitin-mediated degradation of cell cycle G1 regulators, and for the initiation of 
DNA replication. 
FZR1 
Related to pathways such as CDK-mediated phosphorylation and removal of 
Cdc6 and Development of TGF-beta receptor signaling. Substrate-specific adapter for 
the anaphase promoting complex/cyclosome E3 ubiquitin-protein ligase complex, 
degrading substrates to ensure that positive regulators of the cell cycle do not 
accumulate prematurely. 
GOSR1 
Trafficking membrane protein which transports proteins among the endoplasmic 
reticulum and the Golgi and between Golgi compartments, considered an essential 
component of the Golgi SNAP receptor complex. 
HIST1H3E 
H3 histone, basic nuclear protein responsible for the nucleosome structure.  
Transcripts from this gene lack polyA tails but instead contain a palindromic 
termination element. This gene is found in the large histone gene cluster on 
chromosome 6. 
NAP1L3 
Member of the nucleosome assembly protein family. Linked closely to a region of 
genes responsible for several X-linked cognitive disability syndromes. 
RPL10 Ribosomal protein that is a component of the 60S ribosome subunit. 
SCN5A 
Integral membrane protein and tetrodotoxin-resistant voltage-gated sodium channel 
subunit. Found primarily in cardiac muscle and responsible for the initial upstroke of 
the action potential in an electrocardiogram. Defects in this gene are a cause of long 
QT syndrome type 3 
SMAD 
Signal transducer and transcriptional modulator that mediate multiple signaling 
pathways. Transcriptional modulator activated by transforming growth factor-beta 
and is thought to play a role in the regulation of carcinogenesis. 
Table 7: GeneCards database information on fig. 4 relevant nodes (available from: http://www.genecards.org/ 
[23/12/19]) 
Afterwards we analysed their neighbours to identify possible dysregulation 
pathways. Finally, we identified five non-specific gene clusters that represent groups of 
highly related and relevant genes. The green gene cluster includes proteins related to 
DNA transcription regulation. The blue gene cluster is characterised by ribosomal and 
mRNA splicing proteins, thus, generally it is involved in translation. Ubitiquin and 
cytoskeleton-related proteins are included in the red gene cluster. Cytoskeleton and 




axonogenesis, form the yellow protein cluster. Finally, several inflammation-related 
proteins conform the purple gene cluster. 
Apart from applying the classification algorithm, from all ME data, we computed 
FC for all features that were not dropped due to lack of attributes. Table 8 presents the 
expression data for the top 10 most hypo-expressed miRNA. Two miRNA presented 
about 2-fold upregulation: miR-302e and miR-488*. 
P value FC miRNA 
1.80e-09 -3.998 miR-143 
2.80e-09 -3.889 miR-145 
3.98e-08 -3.679 miR-451 
8.98e-12 -3.498 miR-338-3p 
8.26e-11 -3.030 miR-148a 
9.95e-09 -2.783 miR-376c 
2.25e-08 -2.750 miR-126* 
1.27e-11 -2.735 miR-223 
5.58e-09 -2.725 miR-199a-3p, miR-199b-3p 
7.49e-09 -2.697 miR-424 
Table 8: top 10 items from ME dataset (in increasing order of FC) 
From the most de-regulated miRNA, we found interesting documented 
interactions and biological functions for three: miR-145, miR-451 and miR-223. On the 
one hand, Sun et al. (35) identified miR-142 and miR-223 to be haematopoietic miRNA 
and miR-223 to have crucial functions in myeloid lineage development. Even though the 
function of miR-142 wasn’t fully discovered, both microRNAs presented an attenuating 
function on haematopoietic cells and miR-223 upregulated miR-142 expression, thus 
discovering a new regulating pathway between these microRNAs that is very relevant to 
haematopoiesis. 
On the other hand, Hu and colleagues (36) demonstrated the crucial role of miR-
145 in the regulation of TNF-α-mediated signalling and cartilage matrix degradation. 
miRNA expression profiles of TNF-α-stimulated chondrocytes showed that miR-145 
expression was quickly downregulated by TNF-α. They even found that miR-145 directly 
targeted MKK4 (mitogen-activated protein kinase kinase 4) and largely restrained the 
synthesis of several TNF-α-triggered matrix-degrading enzymes. MKK4 hyper-expression 
increased TNF-α-mediated signalling activation, and therefore worsened cartilage 
degradation. Furthermore, they found that intra-articular injection of miR-145 agonist 
to rats with surgery-induced osteoarthritis prevented or decreased cartilage 
destruction. Interestingly, Ohgidani et al. (37) studied TNF-α expression levels in the 
central nervous system in FMS patients by transforming blood cells into microglia-like 
cells. They found that TNF-α was hyper-expressed in FMS microglia-like cells. 
Furthermore, they discovered that there was a moderate correlation between TNF-α 




manifestations. Therefore, the hypo-expression of miR-145 matches the hyper-
expression of TNF-α. Likewise, according to Sun and colleagues (38), miR-451 may 
relieve chronic inflammatory pain by inhibiting microglia activation-mediated 
inflammation via targeting TLR4. They used complete Freund’s adjuvant (CFA)-induced 
inflammatory pain mice model and their results show the expression of miR-451 was 
decreased in spinal microglia. Microglia-mediated neuroinflammation in spinal cord is 
key in the pathogenesis of chronic inflammatory pain. They further confirmed the anti-
inflammatory effects of miR-451, specifically: miR-451 overexpression antagonized 
microglial activation-induced proinflammatory cytokine releases, including IL-6, IL-1β, 
and TNF-α.  The down-regulation of both miR-145 and miR-451 shown in FMS could be 
synergic in their regulation of inflammatory pathways. 
From miRNA selected as the classification probeset, it is interesting to note 
information on: miR-16, miR-21, miR-103, miR-26a and miR-150, apart from the already 
explained implications of miR-223 and miR-451. The first three microRNAs have been 
related to growth cell regulation in some form of cancer cell. On the one hand, Cutrona 
et al. (39) state that chronic lymphocytic leukaemia (CLL) clones lack a critical region 
involving miR-15a and miR-16-1. When those CLL cells were transfected with the miRNA 
mimics they showed a decrease in cell viability in vitro and substantial tumour regression 
in NSG mice previously engrafted with CLL clones. On the other hand, Masoudi and 
colleagues (40) analysed miRNA expression in glioblastoma multiform (GBM) cells. The 
miRNA most involved in GBM pathogenesis was miR-21. Other studies have also 
reported that de-regulation of this miRNA could alter a variety of molecular pathways 
such as insulin-like growth factor-binding protein-3 (IGFBP3), RECK and TIMP3. Finally, 
another study regarding miRNA interaction in cancer cell growth was conducted by Chen 
et al.  (41). They found that miR-103, miR-195 or miR-15b were downregulated in glioma 
tissues and cell lines, the common highly malignant primary brain tumour. These studies 
show that miRNAs can indeed play a part in several key regulatory pathways. Since, to 
our knowledge, there is no evidence of correlation between FMS and cancer, this miRNA 
down-regulation might not have pivotal implication in FMS pathogenesis. However, 
taking into consideration that miRNAs are still subject of study, miR-16, miR-21, miR-103 
might provide further alterations in cell activity in FMS. 
Regarding miR-26a, a study carried out by chinese researchers (42) concluded that 
forced miR-26a/26b expression was able to affect chondrocytes proliferation and 
apoptosis.  They analysed the effect of these miRNAs on chondrocytes to evaluate their 
impact on osteoarthritis. In osteoarthritic mice, the overexpression of miR-26a/26b by 
intra-articular injection significantly attenuated the disease’s progression.  Actually, 
both osteoarthritis and FMS typically present chronic pain (43) and comparing the 
involvement of these miRNAs in both cases might provide new drug targets and or 
treatment. Precisely, some studies reported that FMS patients with comorbid 
osteoarthritis or myofascial pain had improvement in their overall FMS pain and 




potential role of miR-150 in regulating the process of neuropathic pain in a rat model 
established by chronic sciatic nerve injury (CCI).  They showed that overexpression of 
miR-150 greatly alleviated neuropathic pain development and reduced inflammatory 
cytokine expression, including COX-2, IL-6 and TNF-α in CCI rats. They further proved 
that miRNAs are key participators in the pathophysiological course of neuropathic pain.   
7. Conclusions  
o Across most of the studies reviewed, it was recurrent to find that in FMS patients 
there is some dysregulation in neural system genesis and in inflammatory pathways.  
 
o miRNAs are key participators in the pathophysiological course of neuropathic 
pain. We found that TNF-α/miR-145 regulatory pathway might be an important factor 
in FMS aetiology. In addition, miR-150 over-expression alleviates neuropathic pain 
development and reduces inflammatory cytokine expression, including TNF-α, and 
might also contribute to the previous relationship. The hypo-expression of miR-145 and 
miR-451 could be synergic in their regulation of inflammatory pathways.  
 
o Given that some of epigenetic alterations seen in FMS could cause significant 
dysregulation in important proteins and non-coding RNA, they could be potential 
treatment targets. Overexpressed genes could be downregulated with antisense RNA 
molecules, for instance. Epigenetic drugs might also potentially reverse abnormal gene 
expression profiles associated with FMS. 
 
o A SVM-RFE algorithm tested through holdout crossvalidation provided a set of 
56 RNA probes with an accuracy of 95.72% and a set of 20 microRNA probes with 
98.95%. According to our results, miRNA may be the best genetic biomarker to diagnose 
FMS.  There should be further clinical trials and studies to assess diagnostic sensitivity 
and specificity. 
 
o The algorithm, however, needs further improvements like the implementation 
of better internal validation techniques and optimization strategies. It could not include 
as many data points as hoped for and the results of miRNA probes is based on a very 
limited dataset. The results of the algorithm are not meant to be conclusive but to serve 
as a steppingstone to future studies.  
 
o There is a lack of big sample size genetic studies and with precise exclusion 
criteria (to account for FMS comorbities). FMS genetic investigation is still in its infancy 
and the incoming results look promising. We advise future work on the subject to finally 
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